A Multicenter Randomized Phase III Study of Gemcitabine Plus Herceptin Combination Versus the Capecitabine Plus Herceptin Combination in Pretreated Patients With HER-2 Positive Metastatic Breast Cancer.
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2013
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Mar 2007 New trial record.